1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shinpoong Pharmaceutical Co., Ltd.

Shinpoong Pharmaceutical Co., Ltd.

8,680.00
KRW
-500.00
(-5.45%)
-13.88EPS
435.38BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5,308.18
5,374.85
4,596.89
4,093.72
3,731.02
3,542.23
3,813.09
3,952.8
3,675.74
4,087.91
3,908.49
4,324.96
4,573.88
4,444.15
Basic EPS, GAAP
133.65
99
28
-433
25
53
107
100
-225
-691
-1,119
-301
172
-15.16
Free Cash Flow per Basic Share
-129.16
-225.77
171.24
368.06
132.9
571.15
103.92
338.66
-1,488.71
-638.18
-777.65
-415.56
258.5
251.58
Dividend per Share
56.08
38.82
48.31
- -
- -
- -
- -
- -
100.15
- -
- -
- -
- -
- -
Book Value per Share
4,917.42
5,025.88
4,899.36
4,524.05
4,470.02
4,400.34
4,436.06
7,672.6
7,269.12
6,667.35
5,449.16
5,190.08
5,199.84
5,339.2
Tangible Book Value per Share
4,503.29
4,647.87
4,596.65
4,289.06
4,286.95
4,251.95
4,250.28
7,508.97
7,087.05
6,526.68
5,332.07
5,088.47
5,101.49
5,237.83
Basic Weighted Avg Shares
41
41
43
47
50
53
50
50
51
51
51
51
51
54
Sales/Revenue/Turnover
215,963
220,292
195,950
194,147
184,998
187,389
189,722
197,751
189,237
209,288
200,229
221,094
234,681
239,065
Operating Margin (%)
11.49
9.06
2.02
3.93
4.41
4.14
2.95
3.97
-7.56
-16.25
-23.67
-7.7
6.07
1.13
Depreciation Expense
11,581
12,355
12,456
10,016
9,841
11,366
12,314
12,208
12,675
12,803
11,908
11,963
11,393
11,316
Net Income, GAAP
5,438
4,058
1,194
-20,535
1,240
2,804
5,324
5,003
-11,584
-35,377
-57,325
-15,387
8,825
-815
Effective Tax Rate (%)
72.12
71.42
36.58
- -
38.35
45.71
24.21
39.5
- -
- -
- -
- -
0.74
13,304.74
Profit Margin (%)
2.52
1.84
0.61
-10.58
0.67
1.5
2.81
2.53
-6.12
-16.9
-28.63
-6.96
3.76
-0.34
Working Capital
47,677
34,664
38,181
70,386
80,501
84,201
91,003
255,240
204,447
169,375
122,550
113,477
139,826
137,877
LT Debt
30,114
9,834
4,473
8,050
9,550
2,000
7,664
576
213
442
219
4,941
11,500
11,161
Total Equity
190,785
195,366
198,430
218,474
215,878
213,247
214,893
380,095
360,324
330,758
270,782
258,090
270,728
278,036
Return on Invested Capital (%)
2.21
1.72
0.74
- -
1.58
1.36
1.39
1.29
- -
- -
- -
- -
4.65
-116.49
Return on Capital (%)
2.29
1.81
1.51
- -
1.19
1.58
2.61
1.92
- -
- -
- -
- -
3.73
-125.41
Return on Common Equity (%)
2.89
2.12
0.61
-9.92
0.57
1.32
2.51
1.69
-3.15
-10.3
-19.2
-5.87
3.36
-0.31

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
44,356
43,285
42,120
LT Borrowings
11,374
11,082
10,805
LT Finance Leases
126
142
356
Preferred Equity and Hybrid Capital
1,100
1,100
1,100
Shares Outstanding
52
52
52
Market Capitalization
725,985
535,181
435,384

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
206,736
209,120
212,132
Cash, Cash Equivalents & STI
71,506
76,612
72,308
Accounts Receivable, Net
72,538
67,504
72,788
Inventories
58,476
59,101
62,092
Total Current Liabilities
66,909
65,398
74,255
Payables & Accruals
- -
- -
- -
ST Debt
44,356
43,285
42,120
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.4%
-6.27%
4.9%
Free Cash Flow
-21.68%
-159.39%
-162.43%
Net Income, GAAP
-201.11%
-58.92%
-157.35%
Sales/Revenue/Turnover
1.97%
3.71%
6.15%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
54,006
56,027
55,798
55,263
221,094
2025
55,410
58,620
62,610
58,041
234,681
2026
54,526
63,888
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-51
-2
-10
-246.55
-301
2025
-26
61
124
9
172
2026
6
-152
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Je-Man Yoo
Full Time Employees
792
Sector
Health technology
Industry
Pharmaceuticals: major
Address
161, Yeoksam-ro Ansan-si GY South Korea 06246
IPO Date
Jan 20, 1990
Website
shinpoong.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shinpoong Pharmaceutical Co., Ltd. (019170.KS) manufactures and markets pharmaceutical products, including active pharmaceutical ingredients and finished dosage forms, with a focus on antibiotics, antivirals, anticancer agents, painkillers, anti-inflammatory drugs, and anthelmintics. The company produces cephalosporin antibiotics such as ceftriaxone sodium (Cefaxone Inj.), ceftazidime (Tazicef Inj.), and ceftizoxime sodium (Varucefa Inj.); penicillin antibiotics including piperacillin-tazobactam (Lynactam Inj.), ampicillin-sulbactam (Bactacin Inj.), and amoxicillin-clavulanate (Clamoxin Inj.); and diverse finished products like Pyramax (anti-malarial drug), Triam Inj. (triamcinolone acetonide), Bretra Tab. (letrozole), Liveract Infusion Inj. (L-ornithine L-aspartate), Spectinomycin Inj., and Gentrisone Cream (betamethasone, clotrimazole, gentamicin); as well as drugs for hypercholesterolemia, knee osteoarthritis, shoulder periarthritis, surgical adhesion barriers, prescription drugs, wound dressings, health functional foods, and over-the-counter products. Founded in 1962 and headquartered in Seoul, South Korea, Shinpoong operates manufacturing facilities in South Korea, including dedicated plants for cephalosporin and penicillin antibiotics compliant with KGMP and EU-GMP standards, and exports to approximately 50 countries across Europe, America, Africa, Asia, and other regions through distributors and joint ventures. In recent developments, the company signed a supply agreement with EMI Pharm D.O.O. in Serbia for its anti-adhesion barrier Medicurtain, granting exclusive rights in Serbia and Montenegro; continues global expansion of Pyramax following EMA approvals for tablets in 2012 and granules in 2015; and maintains ongoing R&D efforts in APIs and novel therapies through its Central Research Institute.